Physician profile

Ardis K Allison

Pediatrics · O'Fallon, MO

NPI 1487609616

$227.45

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$170.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alexion Pharmaceuticals, INC. $45.34 2023-2024 Strensiq
Sanofi Pasteur INC. $32.71 2019-2023
Supernus Pharmaceuticals, INC. $29.72 2023 Qelbree
Ironshore Pharmaceuticals INC. $27.58 2020-2024
Merck Sharp & Dohme LLC $26.49 2019-2023 Vaxneuvance, M-M-R II, Vaxelis
Tris Pharma INC $17.88 2024 Dyanavel Xr
Kaleo, INC. $17.43 2022
Corium, LLC $16.16 2023 Azstarys
Pfizer INC. $14.14 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ardis K Allison

$227.45

in general payments reported 2019-2025

Years
2019-2024
Top company
Alexion Pharmaceuticals, INC.

https://glasscript.com/doctor/860621/ardis-k-allison

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.